SG11201909058WA - Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers - Google Patents
Peptides and combination of peptides for use in immunotherapy against leukemias and other cancersInfo
- Publication number
- SG11201909058WA SG11201909058WA SG11201909058WA SG11201909058WA SG 11201909058W A SG11201909058W A SG 11201909058WA SG 11201909058W A SG11201909058W A SG 11201909058WA SG 11201909058W A SG11201909058W A SG 11201909058WA
- Authority
- SG
- Singapore
- Prior art keywords
- peptides
- tuebingen
- international
- april
- pct
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 9
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 8
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 238000009169 immunotherapy Methods 0.000 title abstract 3
- 208000032839 leukemia Diseases 0.000 title abstract 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 2
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 230000005975 antitumor immune response Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
00 O O (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 18 October 2018 (18.10.2018) WIPO I PCT omit VIII °nolo OH 1101 (10) International Publication Number WO 2018/189152 A3 (51) International Patent Classification: A61K 39/00 (2006.01) GO1N 33/50 (2006.01) C07K 14/47 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/EP2018/059114 (22) International Filing Date: 10 April 2018 (10.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/483,690 10 April 2017 (10.04.2017) US 10 2017 107 710.3 10 April 2017 (10.04.2017) DE (71) Applicant: IMMATICS BIOTECHNOLOGIES GMBH [DE/DE]; Paul-Ehrlich-StraBe 15, 72076 Tuebingen (DE). (72) Inventors: WALZ, Juliane Sarah; Gartenstrasse 71, 72076 Tuebingen (DE). KOWALEWSKI, Daniel; Den- zenbergstrasse 29, 72074 Tuebingen (DE). DUELER, Markus; Sandgrabenstr. 20, 72119 Ammerbuch (DE). DI MARCO, Moreno; Memmingerstr. 18/1, 72072 Tuebingen (DE). TRAUTWEIN, Nico; Pelargusstr. 2, 70180 Stuttgart (DE). NELDE, Annika; Viktor-Renner-StraBe 27, 72074 Tuebingen (DE). STEVANOVIC, Stefan; Auf der Burg 3, 72074 Tuebingen (DE). RAMMENSEE, Hans-Georg; Sommerhalde 3, 72070 Unterjesingen (DE). HAEN, Sebas- tian; Brombergstr. 15, 72070 Tuebingen (DE). (74) Agent: KRAUSS, Jan B.; Boehmert & Boehmert, Pet- tenkoferstrasse 20 - 22, 80336 Munich (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (88) Date of publication of the international search report: 22 November 2018 (22.11.2018) (54) Title: PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LEUKEMIAS AND OTHER CANCERS (57) : The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor- associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762483690P | 2017-04-10 | 2017-04-10 | |
| DE102017107710 | 2017-04-10 | ||
| PCT/EP2018/059114 WO2018189152A2 (en) | 2017-04-10 | 2018-04-10 | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909058WA true SG11201909058WA (en) | 2019-10-30 |
Family
ID=62116820
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202100324YA SG10202100324YA (en) | 2017-04-10 | 2018-04-10 | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers |
| SG11201909058W SG11201909058WA (en) | 2017-04-10 | 2018-04-10 | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers |
| SG10202100326SA SG10202100326SA (en) | 2017-04-10 | 2018-04-10 | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202100324YA SG10202100324YA (en) | 2017-04-10 | 2018-04-10 | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202100326SA SG10202100326SA (en) | 2017-04-10 | 2018-04-10 | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20220118016A1 (en) |
| EP (1) | EP3609531A2 (en) |
| JP (1) | JP7026970B2 (en) |
| KR (1) | KR20190137858A (en) |
| CN (3) | CN111533799A (en) |
| AU (1) | AU2018253341B2 (en) |
| BR (1) | BR112019021094A2 (en) |
| CA (1) | CA3059645A1 (en) |
| CL (7) | CL2019002878A1 (en) |
| CO (1) | CO2019012071A2 (en) |
| CR (1) | CR20190509A (en) |
| IL (1) | IL269813A (en) |
| MA (1) | MA49123A (en) |
| MX (1) | MX2019012226A (en) |
| MY (1) | MY197772A (en) |
| PE (1) | PE20191617A1 (en) |
| PH (1) | PH12019502300A1 (en) |
| SG (3) | SG10202100324YA (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6772062B2 (en) * | 2013-12-02 | 2020-10-21 | フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． | Cancer immunotherapy |
| MX2019008844A (en) * | 2017-01-26 | 2019-09-10 | Sangamo Therapeutics Inc | B-cell engineering. |
| TW201906859A (en) * | 2017-07-07 | 2019-02-16 | 德商英麥提克生物技術股份有限公司 | Novel peptide and peptide compositions for immunotherapy of lung cancer, including NSCLC, SCLC and other cancers |
| CN113109564A (en) * | 2021-03-15 | 2021-07-13 | 成都益安博生物技术有限公司 | Peripheral blood TCR marker of acute myelocytic leukemia and detection kit and application thereof |
| CN117586344A (en) * | 2022-08-12 | 2024-02-23 | 上海交通大学医学院附属瑞金医院 | Antigenic peptide targeting FLT3-D835 mutation and application thereof in tumor immunotherapy |
| CN117552115B (en) * | 2024-01-12 | 2024-03-26 | 天津鲸鹏生物科技有限责任公司 | Universal antigen peptide library for inducing tumor specific immune response and application thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040005561A1 (en) * | 2000-03-01 | 2004-01-08 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| US20030148321A1 (en) | 2001-08-24 | 2003-08-07 | Iris Pecker | Methods and kits for diagnosing and monitoring hematopoietic cancers |
| US8039218B2 (en) | 2002-11-14 | 2011-10-18 | John Wayne Cancer Institute | Detection of cancer cells in body fluids |
| EP1640452A4 (en) | 2003-05-30 | 2009-12-23 | Nippon Shinyaku Co Ltd | OLIGO DOUBLE-STRANDED RNA INHIBITING THE EXPRESSION OF Bcl-2 AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME |
| US20060275844A1 (en) | 2005-04-19 | 2006-12-07 | Linke Steven P | Diagnostic markers of breast cancer treatment and progression and methods of use thereof |
| WO2007011856A2 (en) | 2005-07-15 | 2007-01-25 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for differential diagnosis of chronic lymphocytic leukemia |
| PT1806358E (en) | 2005-09-05 | 2010-05-28 | Immatics Biotechnologies Gmbh | Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules |
| US20090263832A1 (en) * | 2005-11-30 | 2009-10-22 | Roberto Polakiewicz | Reagents for the Detection of Protein Phosphorylation in Leukemia Signaling Pathways |
| WO2008103905A2 (en) | 2007-02-23 | 2008-08-28 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies that specifically bind irta and methods of use |
| WO2009015841A1 (en) * | 2007-07-27 | 2009-02-05 | Immatics Biotechnologies Gmbh | Composition of tumour-associated peptides and related anti-cancer vaccine |
| GB0721686D0 (en) * | 2007-11-05 | 2007-12-12 | Medinnova As | Polypeptides |
| US20110190157A1 (en) | 2008-08-15 | 2011-08-04 | The Regents Of The University Of California | Biomarkers for Diagnosis and Treatment of Chronic Lymphocytic Leukemia |
| US20120077696A1 (en) | 2009-03-15 | 2012-03-29 | Technion Research And Development Foundation Ltd. | Soluble hla complexes for use in disease diagnosis |
| WO2011035433A1 (en) | 2009-09-23 | 2011-03-31 | University Health Network | Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers |
| WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
| TWI777197B (en) * | 2013-08-05 | 2022-09-11 | 德商伊瑪提克斯生物科技有限公司 | Novel peptides, cells, and their use against several tumors, methods for production thereof and pharmaceutical composition comprising the same |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201408255D0 (en) | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
| GB201411037D0 (en) | 2014-06-20 | 2014-08-06 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL) |
| GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| GB201511191D0 (en) | 2015-06-25 | 2015-08-12 | Immatics Biotechnologies Gmbh | T-cell epitopes for the immunotherapy of myeloma |
| GB201515321D0 (en) * | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201521746D0 (en) | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| GB201521894D0 (en) | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
-
2018
- 2018-04-10 SG SG10202100324YA patent/SG10202100324YA/en unknown
- 2018-04-10 SG SG11201909058W patent/SG11201909058WA/en unknown
- 2018-04-10 AU AU2018253341A patent/AU2018253341B2/en active Active
- 2018-04-10 KR KR1020197032832A patent/KR20190137858A/en not_active Application Discontinuation
- 2018-04-10 MY MYPI2019005841A patent/MY197772A/en unknown
- 2018-04-10 CN CN202010276749.4A patent/CN111533799A/en active Pending
- 2018-04-10 MA MA049123A patent/MA49123A/en unknown
- 2018-04-10 BR BR112019021094-6A patent/BR112019021094A2/en not_active IP Right Cessation
- 2018-04-10 CN CN201880023853.3A patent/CN110944660A/en active Pending
- 2018-04-10 SG SG10202100326SA patent/SG10202100326SA/en unknown
- 2018-04-10 PE PE2019001977A patent/PE20191617A1/en unknown
- 2018-04-10 CR CR20190509A patent/CR20190509A/en unknown
- 2018-04-10 MX MX2019012226A patent/MX2019012226A/en unknown
- 2018-04-10 EP EP18722907.5A patent/EP3609531A2/en active Pending
- 2018-04-10 JP JP2020504441A patent/JP7026970B2/en active Active
- 2018-04-10 CA CA3059645A patent/CA3059645A1/en active Pending
- 2018-04-10 CN CN202011264405.8A patent/CN112521478A/en active Pending
-
2019
- 2019-10-03 IL IL26981319A patent/IL269813A/en unknown
- 2019-10-07 PH PH12019502300A patent/PH12019502300A1/en unknown
- 2019-10-09 CL CL2019002878A patent/CL2019002878A1/en unknown
- 2019-10-29 CO CONC2019/0012071A patent/CO2019012071A2/en unknown
-
2020
- 2020-11-13 CL CL2020002950A patent/CL2020002950A1/en unknown
- 2020-11-13 CL CL2020002953A patent/CL2020002953A1/en unknown
- 2020-11-13 CL CL2020002949A patent/CL2020002949A1/en unknown
- 2020-11-13 CL CL2020002948A patent/CL2020002948A1/en unknown
- 2020-11-13 CL CL2020002952A patent/CL2020002952A1/en unknown
- 2020-11-13 CL CL2020002951A patent/CL2020002951A1/en unknown
-
2021
- 2021-06-23 US US17/356,174 patent/US20220118016A1/en not_active Abandoned
-
2022
- 2022-06-17 US US17/843,412 patent/US11559550B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CL2020002951A1 (en) | 2021-02-26 |
| IL269813A (en) | 2019-11-28 |
| BR112019021094A2 (en) | 2020-05-12 |
| CL2019002878A1 (en) | 2020-03-13 |
| US20220362302A1 (en) | 2022-11-17 |
| CO2019012071A2 (en) | 2020-04-01 |
| US11559550B2 (en) | 2023-01-24 |
| CN111533799A (en) | 2020-08-14 |
| EP3609531A2 (en) | 2020-02-19 |
| SG10202100326SA (en) | 2021-02-25 |
| US20220118016A1 (en) | 2022-04-21 |
| CA3059645A1 (en) | 2018-10-18 |
| CL2020002948A1 (en) | 2021-02-26 |
| AU2018253341B2 (en) | 2022-01-13 |
| SG10202100324YA (en) | 2021-02-25 |
| AU2018253341A1 (en) | 2019-11-14 |
| PH12019502300A1 (en) | 2020-07-06 |
| CL2020002949A1 (en) | 2021-02-26 |
| MX2019012226A (en) | 2020-02-07 |
| CN110944660A (en) | 2020-03-31 |
| MY197772A (en) | 2023-07-13 |
| CN112521478A (en) | 2021-03-19 |
| CL2020002953A1 (en) | 2021-03-12 |
| KR20190137858A (en) | 2019-12-11 |
| MA49123A (en) | 2020-03-25 |
| CR20190509A (en) | 2020-01-08 |
| JP7026970B2 (en) | 2022-03-01 |
| CL2020002952A1 (en) | 2021-02-26 |
| JP2020516313A (en) | 2020-06-11 |
| CL2020002950A1 (en) | 2021-02-26 |
| PE20191617A1 (en) | 2019-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909153UA (en) | Peptides and combination thereof for use in the immunotherapy against cancers | |
| SG11201807590SA (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
| SG11201906198PA (en) | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | |
| SG11201909058WA (en) | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers | |
| SG11201806905UA (en) | Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers | |
| SG11201806951TA (en) | Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers | |
| SG11201807868VA (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
| SG11201807300PA (en) | Uterine cancer treatments | |
| SG11201801384YA (en) | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | |
| SG11201806577UA (en) | Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers | |
| SG11201801756WA (en) | Novel peptides and combination of peptides for use in immunotherapy against various cancers | |
| SG11201801670YA (en) | Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201808629UA (en) | Immunotherapy against melanoma and other cancers | |
| SG11201900955VA (en) | T cell receptors and immune therapy using the same | |
| SG11201809781PA (en) | Novel peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers | |
| SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
| SG11201908023YA (en) | T cell receptors and immune therapy using the same against prame positive cancers | |
| SG11201908527SA (en) | High affinity mage-a1-specific tcrs and uses thereof | |
| SG11201808783XA (en) | Cd80 variant immunomodulatory proteins and uses thereof | |
| SG11201810076WA (en) | Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety | |
| SG11201807279QA (en) | Binding proteins and methods of use thereof | |
| SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
| SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
| SG11201906744VA (en) | Core/shell structure platform for immunotherapy |